Michael E. Roach
Management
Okay, thank you, Jason, and welcome to the call. Good to have you covering the stock. First, I would say that, again, what we've always done is focus on quality growth. I think as you know, in our industry, there is a lot of revenue that is not profitable, and our philosophy has been to ensure that the revenue that we're adding here is quality revenue, and to the extent possible, recurring long-term revenue. And that's the focus that we have. I think if we look at the geographies, we do believe we can continue to grow our North American operations. We've got an excellent platform. We've got a good mix of revenue in North America, especially in Canada. In the U.S., again, we've got an excellent team. We've really grown our U.S. capabilities, and therefore, I think as that market picks up, we're growing with it. We do look for more opportunities in the commercial sector as well next year. We still have our follow-on work, relative to the various health initiatives going on in the U.S. And so we do see opportunities there. And in Europe, as I mentioned, we are seeing the early signs of some positive economic rebound. So right across Europe, we have focused in our plan to see growth in the various entities. We -- we're going to do it gradually, so it'll -- you'll see some movement as we go through the various quarters. Again, in parallel, we're also targeting transformational deals where we're attempting to engage with clients outside the RFP process to talk to them about the benefits of a transformational outsourcing deal that will help them meet their goals. And as you know, from following us over the years, an outsourcing deal can, in 1 or 2 quarters, significantly ramp up your organic growth. So that's kind of how we see it. And then as I mentioned earlier, Jason, we have to accelerate the use of all the levers that we've picked up through the Logica acquisition, bringing capabilities that we have in Europe to North America and vice versa. We're doing quite a bit of that in the manufacturing utility side, cross-selling. And so the combination of that, again, our sense is that we will start to move the needle gradually on the top line, while continuing to drive a healthy accretion rate on the bottom line by picking up the investment, the return on investment we've made last year, the $77 million more we have to invest this year and a better adherence across the company, a more consistent adherence to our operating methods embedded now as a result of the integration.